Диссертация (1154314), страница 20
Текст из файла (страница 20)
Моисеев В.С., Мухин Н.А., Смирнов А.В. и соавт. Сердечно сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции // Российский кардиологический журнал.- 2014. – Т. 8(112).– C. 7-3759. Милованова Л.Ю., Козловская Л.В., Милованов Ю.С., ДобросмысловИ.А. Механизмы нарушения фофсорно-кальциевого гомеостаза в развитиисердечно-сосудистых осложнений у больных хронической болезнью почек.Роль фактора роста фибробластов-23 (FGF-23) и Klotho .. Тер. арх. – 2010.
N. 6. – C. 66-7260. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks ofdeath, cardiovascular events, and hospitalization // N. Eng. J. Med. – 2004. – Vol.351(13). – P. 1296–130561. Seck S.M., Dahaba M., Ka E.F., et al. Mineral and bone disease in blackAfrican hemodialysis patients: a report from Senegal // Nephrourol. Mon. –2012.- Vol. 4(4).
– P. 613-60062.Tyroler H.A. Nutrition and coronary heart disease epidemiology. Advances inExperimental Medicine and Biology // 1995. – Vol. 369. – P. 7–1963. U.S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of EndStage Renal Disease in the United States. National Institutes of Health, NationalInstitute of Diabetes and Digestive and Kidney Diseases, Bethesda. - 200464. Wright J., Hutchison A. Cardiovascular disease in patients with chronic kidneydisease // Vasc.
Health Risk Manag. – 2009. – Vol. 5. – P. 713-72265. Parfey P.S. Cardiac disease in dialysis patients: diagnosis, burden of disease,prognosis, risk factors and management // Nephrol. Dial. Transplant. – 2000. –Vol. 15(5). – P. 58-6866. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidneydisease prior dialysis // Semin Dial. – 2003.
– Vol. 16(2). – P. 101-10567. Disthabanchong S. Vascular calcification in chronic kidney disease:Pathogenesis and clinical implication // World. J. Nephrol. – 2012. – Vol. 1(2). –P. 43-5368. deFilippi C, Wasserman S., Rosanio S., et al. Cardiac troponin T and Creactive protein for predicting prognosis, coronary atherosclerosis, andcardiomyopathy in patients undergoing long-term hemodialysis // JAMA. – 2003.– Vol. 290(3.
– P. 353–359.12769. Middleton R.I., Parfrey P.S., Foley R.N. Left ventricular hypertrophy in therenal patient // Am. J. Soc. Nephrol. – 2001. – Vol. 12. – P. 1079-8470. Ohtake T., Kobayashi S., Moriya H. et al. High prevalence of occultcoronary artery stenosis in patients with chronic kidney disease at the initiation ofrenal replacement therapy: An angiographic examination // JAMA. – 2005.
– Vol.16. – P. 1141–114871. Briet M., Burns K.D. Chronic kidney disease and vascular remodeling:molecular mechanism and clinical implication // Clin. Sci. – 2012. – Vol. 123(7). –P. 399-41672. McCullough P.A., Assad H. Diagnosis of cardiovascular disease in patientswith chronic kidney disease // Blood. Purif.
– 2012. – Vol. 33(1-3). – P. 112-11873. Block G.A., Hulbert-Shearon T.E., Levin N.W., et al. Association of serumphosphorus and calcium-phosphate product with mortality risk in chronichemodialysis patients: a national study // Am. J. Kidney Dis. – 1998. – Vol. 31(4).– P. 607-61774. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels andmortality risk among people with chronic kidney disease // J. Am. Soc. Nephrol. –2005.
– Vol. 16(2). – P. 520-52875. Hruska K.A. Mathew S., Lund R. Hyperphosphatemia of Chronic KidneyDisease // Kidney Int. – 2008. – Vol. 74(2). – P. 148-15776. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В., Мухин Н.А.Сывороточные уровни морфогенетических белков – фактора ростафибробластов-23 (FGF-23) и Клото (Klotho) при ХБП: клиническое значение// Клин. нефрол.
– 2013. – N. 2. – C. 10-1877. White K.E., Carn G., Lorenz-Depiereux B., et al. Autosomal-dominanthypophosphatemic rickets (ADHR) mutations stabilize FGF-23 // Kidney Int. –2001. – Vol. 60(6). – P. 2079-208678. Yamashita T. Structural and biochemical properties of fibroblast growthfactor 23 // Ther. Apher. Dial. – 2005. – Vol. 9(4). – P. 313–31879. Kardami E.et al. Fibroblast growth factor 23 isoforms and cardiac hypertrophy// Cardiovasc.
Res. – 2004. – Vol. 63(3). – P. 458–46680. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growthfactor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus ofthe brain // Biochem. Biophys. Res. Commun. – 2000. – Vol. 277(2). – P. 49449881. Shimada T., Kakitani M., Yamazaki Y.
et al. Targeted ablation of Fgf23demonstrates an essential physiological role of FGF23 in phosphate and vitamin Dmetabolism // J. Clin. Invest. 2004. – Vol. 113(4). – P. 561–56882. Takeshita K. et al. Sinoatrial node dysfunction and early unexpected death ofmice with defect of Klotho gene expression // J. Circulation. – 2004. – Vol.
109(14). – P. 1776-178283. Westerberg P,A., Linde T., Wikstrom B. Regulation offibroblast growthfactor-23 in chronic kidney disease //. Nephrol. Dial. Transplant. - 2007. 22(11) . – P. 3202-320712884. Sitara D., Razzaque M.S., Hesse M. et al. Homozygous ablation of fibroblastgrowth factor- 23 results in hyperphosphatemia and impaired skeletogenesis, andreverses hypophosphatemia in Phex-deficient mice // Matrix. Biol. – 2004. - Vol.23(7). – P.
421–43285. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator ofvitamin D metabolism and phosphate homeostasis // J. Bone. Miner. Res. – 2004.– Vol. 19(3). – P. 429–43586. Khosravi A., Cutler C.M., Kelly M.H. et al. Determination of the eliminationhalf-life of fibroblast growth factor-23 // J. Clin. Endocrinol. Metab. – 2007. – Vol.92. – P. 2374–237787. Yamazaki Y., Okazaki R., Shibata M. et al. Increased circulatory level ofbiologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia // J. Clin.
Endocrinol . Metab. – 2002. – Vol. 87(11). – P. 4957–496088. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblastgrowth factor receptor activation // Cytokine Growth Factor Rev. – 2005. – Vol.16(2). – P. 107–13789. Kuro-o M. Klotho and chronic kidney disease – Whats new? // Nephrol. Dial.Transplant. – 2009 . – Vol. 24(6). – P. 1705-170890. Semba R.D., Cappola A.R., Sun K. et. al. Plasma Klotho and cardiovasculardisease in adults // Am. J. Gtriatr. Soc. – 2011. – Vol. 59(9). – P. 1596-160191. Maltese G., Karalliedde J. The putative Role of the Antiageing Protein Klothoin Cardiovascular and Renal disease // Int. J. Hypertens. – 2012.
– P. 75746992. Hu M.C., Shi M., Quinones H., et al. Klotho deficiency is an early biomarkerof renal ischemia-reperfusion injury and its replacement is protective // KidneyInt. – 2010. – Vol. 78. – P. 1240–125193. Hu M.C., Kuro-o M, Moe O.W. Selected Klotho and Chronic Kidney disease //Advances in Experimental Medicine and Biology. – 2012.
– Vol. 728. - P. 126157; doi: 10.1007/978-1-4614-0887-1_994. Matsumura Y., Alzawa H., Shiraki-Lida T. et al. Identification of the humanKlotho gtnt and its two transcripts encoding membrane and secreted Klotho protein// Biochemical and Biophysical Researh Communication. – 1998. – Vol. 242(3). –P. 626-63095. Haruna M. Y., Kashihara N., Satoh et al. Amelioration of progressive renalinjury genetic manipulation of Klotho gene // Procceding of the NationalAcademy of Sciences of the United States of America.
– 2007. – Vol. 104(7). – P.2331-233696. Sugiura H., Yoshida T., Mitobe M. et al. Klotho reduses apoptosis inexperimental ischaemic acute renal kidney injury via HSP-70 // Nephrol. Dial.Transplant. – 2010. – Vol. 25(1). – P. 60-6897. Kuro-o M., Matsumura Y., Aizawa H. et al. Mutation of the mouse klotho geneleads to a syndrome resembling ageing // Nature. – 1997. – Vol.
390(6655). – P.45–5112998. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renalosteodystrophy // Clin J Am Soc Nephrol. – 2011. – P. 6:877–88299. Kuro-o M. An overview of FGF-FGFR Signaling // Endocrine FGFs andKlothos. – 2012. – Vol. 728. – P. 1-2100. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblastgrowth factor receptor activation // Cytokine Growth Factor Rev. – 2005. – Vol.16(2). – P. 107–137101. Brandenburg V.M., Kramann R., Koos R. Relationship between sclerostinand cardiovascular calcification in hemodialysis patients: a cross-sectional study.BMC // Nephrol.
– 2013. – Vol. 14. – P. 219.102. Kosaku N. Relationship between Fibroblast Growth Factor-23 and MineralMetabolism in Chronic Kidney Disease // Int. J. Nephrol. – 2010. - Article ID167984103. Kurosu H., Ogawa Y., Miyoshi M. et al. Regulation of fibroblast growthfactor -23 signaling by Klotho // J. Biolog. Chem. – 2006. – Vol. 281(10). – P.6120–6123104. Cha S.K., Ortega B., Kurosu H. et al. Removal of sialic acid involving Klothocauses cell-surface retention of TRPV5 channel via binding to galectin-1 // Proc.Natl. Acad. Sci. – 2008.
– Vol. 105. – P. 9805–9810105. Chang Q., Hoefs S., van der Kemp A.W. et al. The β-glucuronidase klothohydrolyzes and activates the TRPV5 channel. Science. 2005; 310: 490–493106. Cha S.K., Hu M.C., Kurosu H. et al. Regulation of renal outer medullarypotassium channel and renal K+ excretion by Klotho // Mol. Pharmacol. – 2009. –Vol. 76. – P. 38–46107. Saito Y., Nakamira T., Ohyama Y.
et al. In vivo Klotho gene delivery protectsagainst endothelial dysfunction in multiple risk factor syndrome // Biochem.Biophys. Res. Commun. – 2000. – Vol. 278(2). – P. 767-772108. Hu M.C., Shi M., Zhang J. et al. Klotho deficiency causes vascularcalcification in chronic kidney disease // J. Am.
Soc. Nephrol. – 2011. – Vol. 22 .– P. 124–136109. Inaba M., Okuno S., Imanishi Y. et al. Role of fibroblast growth factor-23 inperipheral vascular calcification in non-diabetic and diabetic hemodialysis patients// Osteoporos Int. – 2006. – Vol. 17.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
